Skip to main content
. 2017 Aug 17;7:8596. doi: 10.1038/s41598-017-08674-8

Figure 6.

Figure 6

Performance of the µmLchip in the analysis of clinical samples. A patient with a heterozygous JAK2 V617F mutation (A) the result of the chip-based LAMP; (B) agarose gel electrophoresis of the LAMP-amplified products from Fig. 6A); a patient with the MPL W515K mutation (C) the result of the chip-based LAMP; D: agarose gel electrophoresis of the LAMP-amplified products from Fig. 6C); a patient with the MPL W515L mutation (E) the result of the chip-based LAMP; (F) agarose gel electrophoresis of the LAMP-amplified products from Fig. 6E); a patient with JAK2 V617F and MPL W515 wild-type (G) the result of the chip-based LAMP; (H) agarose gel electrophoresis of the LAMP-amplified products from Fig. 6G); and a patient with both MPL W515K and JAK2 V617F mutations (I) the result of the chip-based LAMP; (J) agarose gel electrophoresis of the LAMP-amplified products from Fig. 6I). The sequencing results of cloned PCR products are also shown (Fig. 6K). Lanes 1–5 represent the chambers: JAK2 V617F wild-type, JAK2 V617F mutation, MPL W515K mutation, MPL W515L mutation, and MPL W515 wild-type, respectively. Lane M, 1000 bp ladder size markers. Microchambers P1-P5 represent the positive control for microchamber 1–5, respectively. The microchamber N* represent the negative control.